Iron Chelating Agents
This graph shows the total number of publications written about "Iron Chelating Agents" by people in the URMC Research Network by year, and whether "Iron Chelating Agents" was a major or minor topic of these publication.
Below are the most recent publications written about "Iron Chelating Agents" by people in Profiles.
-
Zhao Y, Rempe DA. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J Cereb Blood Flow Metab. 2011 Jun; 31(6):1412-23.
-
Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010 Nov; 52(5):1671-779.
-
Imran F, Phatak P. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes. Expert Rev Pharmacoecon Outcomes Res. 2009 Aug; 9(4):297-304.
-
Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009 Jan; 25(1):139-47.
-
Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol. 2008 Apr; 83(4):263-70.
-
Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007 Oct; 47(10):1919-29.
-
Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007; 25(4):329-42.
-
Borisenko GG, Kagan VE, Hsia CJ, Schor NF. Interaction between 6-hydroxydopamine and transferrin: "Let my iron go". Biochemistry. 2000 Mar 28; 39(12):3392-400.
-
Marin PC, Im MJ, Girotto JA, Borschel G, Bickel KD. Effects of hydroxyethyl-starch-bound deferoxamine on ischemia/reperfusion injury in chronic nerve compression. J Reconstr Microsurg. 1998 Oct; 14(7):485-90.
-
Weinberg GA. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994 May; 38(5):997-1003.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
